Clinical Trial Update: Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations [Phase 1]

View source ↗

Summary

This Phase 1 trial update evaluates TYRA-430 in hepatocellular carcinoma and FGFR-altered solid tumors, highlighting safety signals and preliminary anti-tumor a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TYRA-430 (TYRA-430)

Snippet

Sponsor: Tyra Biosciences, Inc | Conditions: Metastatic Hepatocellular Carcinoma, Solid Tumors | Phase 1 | Status: RECRUITING